• Prof. Halidou Tinto – Principal Investigator (IRSS-URCN, Nanoro, Burkina Faso)

• Dr. Angela M. Minassian – Chief Investigator (University of Oxford, UK)

• Professor Simon J Draper – Senior Laboratory Investigator

Dr Magloire Natama

This Phase IIb, double-blind, randomised, controlled clinical trial is designed to evaluate the safety, immunogenicity, and efficacy of two blood-stage malaria vaccine candidates, RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM, in healthy infants aged 5-17 months in Burkina Faso.
The trial is being conducted at a single site (IRSS-URCN, Nanoro). A total of 480 infants are enrolled and randomised into five groups receiving either one of the study vaccines or a rabies vaccine (control) on monthly or delayed dosing regimens. Each participant will be followed for 12 months after the final vaccination. The primary objective is to assess the protective efficacy of the vaccines against clinical malaria within six months of the last vaccination. The study also examines safety and immune responses over a 12-month period.

European and Developing Countries Clinical Trials Partnership (EDCTP)
(via the Multi-Stage Malaria Vaccine Consortium – MMVC)

                       University of Oxford

• Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso

• University of Oxford, UK

2023